BDX logo

Becton, Dickinson and Company Stock Price

NYSE:BDX Community·US$55.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 38 Fair Values set on narratives written by author

BDX Share Price Performance

US$193.90
-28.08 (-12.65%)
US$201.49
Fair Value
US$193.90
-28.08 (-12.65%)
3.8% undervalued intrinsic discount
US$201.49
Fair Value
Price US$193.90
AnalystConsensusTarget US$201.49

BDX Community Narratives

AnalystConsensusTarget·
Fair Value US$201.49 3.8% undervalued intrinsic discount

Advanced Diagnostics And Tissue Regeneration Will Expand Decentralized Healthcare

0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative

Trending Discussion

Updated Narratives

BDX logo

BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds

Fair Value: US$201.49 3.8% undervalued intrinsic discount
19 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Established dividend payer and fair value.

2 Risks
3 Rewards

Becton, Dickinson and Company Key Details

US$21.8b

Revenue

US$11.5b

Cost of Revenue

US$10.4b

Gross Profit

US$8.7b

Other Expenses

US$1.7b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
5.88
47.43%
7.68%
75.5%
View Full Analysis

About BDX

Founded
1897
Employees
72000
CEO
Thomas Polen
WebsiteView website
www.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Recent BDX News & Updates

Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Recent updates

No updates